New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
14:21 EDTACTActavis price target raised to $198 from $180 at Argus
Argus increased its price target on Actavis after raising its 2013 adjusted EPS estimate above the company's guidance. The firm is upbeat about the outlook for generic drug companies in general, and predicts that Actavis will deliver mid-teens organic earnings growth in the near-term. It keeps a Buy rating on the stock.
News For ACT From The Last 14 Days
Check below for free stories on ACT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTACTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTACTDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information
July 17, 2014
15:42 EDTACTDepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
July 16, 2014
11:28 EDTACTLeon Cooperman gives 12 stock picks at CNBC conference
Subscribe for More Information
11:16 EDTACTCooperman lists Actavis, Citigroup, KKR among top-picks, CNBC says
Subscribe for More Information
09:12 EDTACTLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information
July 11, 2014
16:31 EDTACTActavis confirms generic Diclegis patent challenge
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use